Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Total Liabilities

As of the most recent data (March 2026), BLACR shows a total liabilities of $45M. That compares with $42M in the prior-year period — up 6.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLACR's total liabilities is now $45M (was $42M) — a 6.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 is outperforming or lagging.

Tracking BLACR's total liabilities over time shows whether Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 is scaling, shrinking, or reshaping that part of the business. The current reading is $45M That compares with $42M in the prior-year period — up 6.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $45M) with ownership activity and broader fundamentals.